Icosavax
Facts
- HQ
- Seattle
- Sectors
- Biotechnology, Vaccines, Biotech
- Stage
- Public
- Total raised
- $129.7M SEC Form D filings Total of this company's SEC Form D filings
- Last round
- $99.7M · Mar 2021 SEC Form D
Nobel Laureate David Baker Drives Protein Design Innovation and Startup Growth at University of Washington
David Baker, Nobel Prize winner and head of the Institute for Protein Design at the University of Washington, is focused on advancing protein design research and entrepreneurship, having helped spawn over 20 startups in Seattle's biotech hub. He plans to continue accelerating scientific innovation in the field, which develops new proteins for therapeutics, vaccines, and materials.
University of Washington’s David Baker Credits Open-Code Rosetta Commons for Protein Design Startup Success
David Baker, director of the University of Washington’s Institute for Protein Design (IPD), emphasizes open code sharing as key to the institute’s success in creating protein design startups. The IPD’s collaborative Rosetta Commons consortium has enabled widespread development of protein design tools, fostering innovation and spinouts in biotech.
AstraZeneca to Acquire UW Spinout Icosavax for Up to $1.1 Billion to Boost Respiratory Vaccine Development
AstraZeneca announced it will acquire Seattle-based biotech spinout Icosavax, founded at the University of Washington, for up to $1.1 billion to accelerate development of vaccines targeting respiratory viruses. Icosavax's shares surged over 40% after the deal, which values the company at a 43% premium and aims to advance its lead RSV and hMPV vaccine candidate.
